First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

European Journal of Cancer

Volumn 81, Issue , 2017, Pages 191-202

  Carrato, Alfredo ^a   Abad, Albert ^b,p   Massuti, Bartomeu ^c   Grávalos, Cristina ^d   Escudero, Pilar ^e   Longo Muñoz, Federico ^a   Manzano, José Luis ^b   Gómez, Auxiliadora ^f   Safont, María José ^g   Gallego, Javier ^h   García Paredes, Beatriz ⁱ   Pericay, Carles ^j   Dueñas, Rosario ^k   Rivera, Fernando ^l   Losa, Ferrán ^m   Valladares Ayerbes, Manuel ^n,q   González, Encarnación ^o   Aranda, Enrique ^f  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Alicante Hospital   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e Hospital Clinieo Universitario Lozano Blesa   (Spain)

^f UNIVERSITY OF CÓRDOBA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j Servicio de Oncología Médica   (Spain)

^k Jaen Hospital Complex   (Spain)

^l HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^m L Hospitalet General Hospital   (Spain)

ⁿ UNIVERSITY OF A CORUÑA   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^p Oncology Unit   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

more..

Author keywords

First line; FOLFIRI; FOLFOX; Liver limited disease; Metastatic colorectal cancer; Panitumumab; Resection

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; SECONDARY; SPAIN; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SPAIN; SURVIVAL ANALYSIS;

EID: 85020924057     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.04.024     Document Type: Article

References (34)

1. Douillard, J.-Y., Oliner, K.S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034, 10.1056/NEJMoa1305275.
2. Schwartzberg, L.S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L., Hecht, J.R., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32 (2014), 2240–2247, 10.1200/JCO.2013.53.2473.
3. Abad A, Massuti B, Grávalos C, et al. Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study. Poster presented at the ASCO 50th Annual Meeting, May 30-June 3, 2014, Chicago, IL; Abstract # 3560 and Poster. Available at:: http://meetinglibrary.asco.org/content/97302?format=posterImg&poster=1. [Accessed 14 November 2016].
4. Karthaus, M., Hofheinz, R.D., Mineur, L., Letocha, H., Greil, R., Thaler, J., et al. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer 115 (2016), 1215–1222, 10.1038/bjc.2016.343.
5. NCCN Clinical Practice Guidelines In Oncology: Colon Cancer v.2.2016. Available at:: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [Accessed 14 November 2016].
6. Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27 (2016), 1386–1422, 10.1093/annonc/mdw235.
7. Nathan, H., de Jong, M.C., Pulitano, C., Ribero, D., Strub, J., Mentha, G., et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg, 210, 2010, 10.1016/j.jamcollsurg.2009.12.041 755–64, 764–6.
8. Folprecht, G., Grothey, A., Alberts, S., Raab, H.-R., Köhne, C.-H., Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005), 1311–1319, 10.1093/annonc/mdi246.
9. Adam, R., Avisar, E., Ariche, A., Giachetti, S., Azoulay, D., Castaing, D., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8 (2001), 347–353.
10. Giacchetti, S., Itzhaki, M., Gruia, G., Adam, R., Zidani, R., Kunstlinger, F., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999), 663–669.
11. Ye, L.-C., Liu, T.-S., Ren, L., Wei, Y., Zhu, D.-X., Zai, S.-Y., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31 (2013), 1931–1938, 10.1200/JCO.2012.44.8308.
12. Petrelli, F., Barni, S., Anti-EGFR agents for liver metastases. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis 27 (2012), 997–1004, 10.1007/s00384-012-1438-2.
13. Bokemeyer, C., Bondarenko, I., Hartmann, J.T., de Braud, F., Schuch, G., Zubel, A., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22 (2011), 1535–1546, 10.1093/annonc/mdq632.
14. Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33 (2015), 692–700, 10.1200/JCO.2014.59.4812.
15. Folprecht, G., Gruenberger, T., Bechstein, W., Raab, H.-R., Weitz, J., Lordick, F., et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM-study). Ann Oncol 25 (2014), 1018–1025, 10.1093/annonc/mdu088.
16. Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 1626–1634, 10.1200/JCO.2007.14.7116.
17. Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007), 1658–1664, 10.1200/JCO.2006.08.1620.
18. Van Cutsem, E., Siena, S., Humblet, Y., Canon, J.-L., Maurel, J., Bajetta, E., et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19 (2008), 92–98, 10.1093/annonc/mdm399.
19. Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28 (2010), 4697–4705, 10.1200/JCO.2009.27.4860.
20. Peeters, M., Price, T.J., Cervantes, A., Sobrero, A.F., Ducreux, M., Hotko, Y., et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 25 (2014), 107–116, 10.1093/annonc/mdt523.
21. Nemunaitis, J., Cox, J., Meyer, W., Courtney, A., Mues, G., Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). Am J Clin Oncol 20 (1997), 527–529.
22. Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247, 10.1016/j.ejca.2008.10.026.
23. Piessevaux, H., Buyse, M., Schlichting, M., Van Cutsem, E., Bokemeyer, C., Heeger, S., et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 31 (2013), 3764–3775, 10.1200/JCO.2012.42.8532.
24. Modest, D.P., Laubender, R.P., Stintzing, S., Giessen, C., Schulz, C., Haas, M., et al. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol Stockh Swed 52 (2013), 956–962, 10.3109/0284186X.2012.752580.
25. Douillard, J.Y., Siena, S., Peeters, M., Koukakis, R., Terwey, J.-H., Tabernero, J., Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 51 (2015), 1231–1242, 10.1016/j.ejca.2015.03.026.
26. Rivera, F., Karthaus, M., Randolph, J., Fasola, G., Re Canon, J.L., Koukakis, R., et al. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in wild-type RAS metastatic colorectal carcinoma: tumour response outcomes beyond RECIST. J Clin Oncol, 33(Suppl 3), 2015 Abstract 660 & Poster (D2).
27. Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23 (2005), 4866–4875, 10.1200/JCO.2005.07.113.
28. Bennett, L., Zhao, Z., Barber, B., Zhou, X., Peeters, M., Zhang, J., et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer 105 (2011), 1495–1502, 10.1038/bjc.2011.409.
29. Folprecht, G., Gruenberger, T., Bechstein, W.O., Raab, H.-R., Lordick, F., Hartmann, J.T., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11 (2010), 38–47.
30. Ocvirk, J., Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol, 16, 2010, 3133, 10.3748/wjg.v16.i25.3133.
31. Stintzing, S., Modest, D.P., Rossius, L., Lerch, M.M., von Weikersthal, L.F., Decker, T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17 (2016), 1426–1434, 10.1016/S1470-2045(16)30269-8.
32. Ye, L., Wei, Y., Zhu, D., Chen, T., Xu, J., Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab. J Gastroenterol Hepatol 30 (2015), 674–679, 10.1111/jgh.12847.
33. Douillard, J.Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25 (2014), 1346–1355, 10.1093/annonc/mdu141.
34. Abad, A., Figueras, J., Valls, C., Carrato, A., Pardo, F., Díaz-Rubio, E., et al. Guidelines for the detection and treatment of liver metastases of colorectal cancer. Clin Transl Oncol 9 (2007), 723–730.